Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Simvastatin (Primary)
- Indications Lipid metabolism disorders; Low HDL cholesterol; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SILHOUETTE
- Sponsors Merck & Co; Organon
- 22 Nov 2006 New trial record.